Regeneron Pharmaceuticals

Open: 843.0 Close: 836.85 Change: -6.15

What an AI can tell you about Regeneron Pharmaceuticals Company Inc Stock before investing.

How much time have you spent trying to decide whether investing in Regeneron Pharmaceuticals? Many investors start with the dream of being free. They expect to find on the stock market an option to have time to develop their own interests and hobbies. That is, a way to escape a 9 to 5 job. However, investment is complex and investors end up spending whole days (and nights) trying to figure out which the right stock to invest is. The dream of stock investing becomes the nightmare of facing infinity amounts of information. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: …

Concept Map

Semantic Network

Stock Summary

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases. The company's products include EYLEA injection to treat neovascular age-related macular degeneration.

Today's Summary

Regeneron Pharmaceuticals Inc. stock rises monday, still underperforms market - marketwatch.com. ReGN -0.81% SPX - 0.01% DJIA +0.04% AMGN -6.10% GILD +1.62% ReGN stock rises monday.

Today's News

Regeneron Pharmaceuticals Inc. stock rises monday, still underperforms market - marketwatch.com. ReGN -0.81% SPX - 0.01% DJIA +0.04% AMGN -6.10% GILD +1.62%. Regeneron Pharmaceuticals Estimates* in USD Yearly Quarterly   2023 2024 2025 2026 2027 Revenue 12,786 13,404 13,955 14,475 15,413. P/E ratio 19.73 18.83 18.41 17.41 16.87 16.26. Dupixent® (dupilumab) sBLA for Treatment of Eosinophilic Esophagitis (EoE) in Children Aged 1 to 11 accepted for FDA Priority Review 9/26/2023 Regeneron Completes Acquisition of Decibel Therapeutics, Adding Promising Gene Therapy Programs for Hearing Loss. The current Regeneron Pharmaceuticals [ REGN ] share price is $843.47 USD today. The current trend is moderately bullish and REGN is experiencing slight buying pressure. The Score for REGN is 64, which is 28% above its historic median score of 50, and infers lower risk than normal. Cantor Fitzgerald Maintains Regeneron Pharmaceuticals (REGN) Neutral Recommendation Cantor Fitzgerald maintains Regeneron pharmaceuticals (regn) neutral recommendation. The average one-year price target for Regeneron is 925.63.50. The projected annual revenue for Regeneran Pharmaceuticalsis 12,803MM. Regeneron Pharmaceuticals (NASDAQ:regn) price target increased to $850.00 by analysts at cantor fitzgerald - defense world.com.

Stock Profile

"Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat neovascular age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration and license agreements with Sanofi; Bayer; Teva Pharmaceutical Industries Ltd.; Mitsubishi Tanabe Pharma Corporation; Alnylam Pharmaceuticals, Inc.; Roche Pharmaceuticals; and Kiniksa Pharmaceuticals, Ltd., as well as has an agreement with the U.S. Department of Health and Human Services, as well as with Zai Lab Limited; Intellia Therapeutics, Inc.; Biomedical Advanced Research Development Authority; and AstraZeneca PLC. The company was incorporated in 1988 and is headquartered in Tarrytown, New York."

Keywords

Are looking for the most relevant information about Regeneron Pharmaceuticals? Investor spend a lot of time searching for information to make investment decisions in Regeneron Pharmaceuticals. This task is often burdensome and consumes huge amounts of free time. It also leads to mistakes due to fatigue and bounded rationality. As a solution, we programmed an artificial intelligence that reads the whole internet and the uses natural language processing and vectorizers to summarize the information. Usually, the AI reads several hundred pages and summarize it to a short document. This document presents our results. We found that the most common words in the internet about Regeneron Pharmaceuticals are: Regeneron, Pharmaceuticals, REGN, price, USD, current, Cantor, and the most common words in the summary are: regeneron, pharmaceutical, job, stock, watch, introduction, episode, . One of the sentences in the summary was: stock rises monday, still underperforms market - marketwatch.com. Other searches related to this term that the AI found were: stockmarketlive, livestock, stockmarketforbeginners, thestockmarket, stockmarkettoday, stockmarkettrading, stockmarketstocks, todaystockmarket, thestockmarket, marketnews, stockmarketnews, whatisstockmarket, usstockmarket, stockmarketopen. #regeneron #pharmaceutical #job #stock #watch #introduction #episode.